THERAPEUTIC EFFECTS OF HYALURONIC ACID INTRA-ARTICULAR INJECTION IN OSTEOARTRITIS

October 14, 2014

THERAPEUTIC EFFECTS OF HYALURONIC ACID INTRA-ARTICULAR INJECTION IN OSTEOARTRITIS

This is an automatically generated default intro template – please do not edit.

General information
Title:	THERAPEUTIC EFFECTS OF HYALURONIC ACID INTRA-ARTICULAR INJECTION IN OSTEOARTRITIS
Meta keywords:
Meta description:
Images information
Images path absolute:	/home/jmedarr/public_html/images/stories/com_form2content/p2/f271
Images path relative:	com_form2content/p2/f271
Thumbs path absolute:
Thumbs path relative:
Fields information
Article_Title:	THERAPEUTIC EFFECTS OF HYALURONIC ACID INTRA-ARTICULAR INJECTION IN OSTEOARTRITIS
Authors:	Drd. Radu Grigore-Serban 1*, DR. Silviu Vlad2, Drd. Razvan Vicas3, Dr. Dan Fruja4, Prof. Dr. Alexandru Pop5
Affiliation:	1- General practitioner 2- Dr primary specialist orthopedics Spitalul Clinic Judetean de Urgenta Oradea 3- Rezident orthopedics Spitalul Clinic Judetean de Urgenta Oradea 4- Dr primary specialist orthopedics Spitalul Clinic Judetean de Urgenta Arad 5- Dr primary specialist orthopedics
Abstract:	This study investigates the safety and efficacy of intra-articular (IA) sodium hyaluronate (HA) in the treatment of synovial joint osteoarthritis. This is a prospective, observational study. The patients were given five IA of HA at interval of one week. Efficacy included self-reported pain Visual Analog Scale (VAS) and the NSAID intake. The patients did not report any adverse reaction during the study. The study shows that IA HA injection decreases the pain (VAS) and reduces the NSAID intake in OA.
Keywords:
References:	Dahl LB, Dahl IM, Engstrom-Laurent A, Granath K. Concentration and molecular weight of sodium hyaluronate in synovial fluid from patients with rheumatoid arthritis and other arthropathies. Ann Rheum Dis. 1985 DeVane CL. Substance P:a new era, a new role. Pharmacotherapy 2001 Fries JF. NSAID gastropathy: the second most deadly rheumatic disease. Epidemiology andrisk appraisal. J Rheumatol 1991 Frizziero L, Govoni E, Bacchini P. Intra-articular hyaluronic acid in the treatment of osteoarthritis of the knee :clinical and morphological. Clinical Exp Rheum 1998 Foti C, Cisari C, Carda S, Giordan N, Rocco A, Frizziero A, Della Bella G. A prospective observational study of the clinical efficacy and safety of intra-articular sodium hyaluronate (MW 1500-2000 KDa; Hyalubrix®) in synovial joints with osteoarthritis European journal of psychical and rehabilitation medicine vol 47 2011 Griffin MR, Yared A, Ray WA. Non steroidal antiinflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol 2000 Hayes Hyaluronic Acid/Viscosupplementation A Health Technology Assessment Prepared for Washington State Health Care Authority FINAL REPORT – October 14, 2013 Henry D. Non-steroidal anti-inflammatory drugs and the risk of development of congestive cardiacfailure and functional renal impairment. Proceedings of the international conference on inflammopharmacology, San Francisco, 1997. Karlsson J, Sjögren LS, Lohmander LS. Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double-blind, parallel-design multicenter study. Rheumatology 2002 Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG, Liang MH, Pillemer SR, Steen VD, Wolfe F: Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998 Lussier A, Cividino AA, McFarlane CA, Olszynski WP, Potashner WJ, De Medicis R. Viscosupplementation with hylan for the treatment of osteoarthritis:findings from clinical practice in Canada. J Rheumatol 1996 Marshall KW. Viscosupplementation for osteoarthritis: current status, unresolved issues and future directions. J Rheumatol. 1998 Migliore A. Hip viscosupplementation under ultra-sound guidance riduces NSAID consumption in symptomatic hip osteoarthritis patients in a long follow-up. Data from italian registry 2011 Moore RA, Philips CJ. Cost of NSAID adverse effects to the UK National Health Service. J Med Econ 1999 National Center for Health Statistics: Prevalence of osteoarthritis in adults by age, sex, race and geographic area: United States 1960-62. Vital and Health Statistics no. 15, series 11 Washington, DC: Government Printing Office; 1966. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med 2000 Schieb F. Intraartikular injizierte Hyaluronsaure bei Arthropathien. Arthritis Rheum 2003 Straube S, Tramer MR, Moore RA, Derry S, Mcquai HJ. Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use. BMC Gastroenterol 2009 Towheed T, Shea B, Wells G, Hochberg M. Analgesia and non-aspirin, non steroidal anti-inflammatory drugs for osteoarthritis of the hip (Cochrane review). In: The Cochrane library, issue 1. Oxford: Update Software, 2000 Yasui T, Akatsuka M, Tobetto K. Effects of hyaluronan on the production of stromelysin and tissue inhibitor of metalloproteinase-1 (TIMP-1) in bovine articular chondrocytes. Biomed Res 1992 Zhang W, Moskowitz RW, Nuki G, Abramsons S, Altman RD, Arden N, Bierma-Zeistra S, Brandt KD, Croft P, Doherty M, Dougades M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence- based expert consensus guidelines. Osteoarthritis Cartilage 2008;
Read_full_article:	pdf/vol16/iss1-4/15 JMA 2013 Radu Grigore-Serban.pdf
Correspondence:

	Read full article
Article Title:	THERAPEUTIC EFFECTS OF HYALURONIC ACID INTRA-ARTICULAR INJECTION IN OSTEOARTRITIS
Authors:	Drd. Radu Grigore-Serban 1*, DR. Silviu Vlad2, Drd. Razvan Vicas3, Dr. Dan Fruja4, Prof. Dr. Alexandru Pop5
Affiliation:	1- General practitioner 2- Dr primary specialist orthopedics Spitalul Clinic Judetean de Urgenta Oradea 3- Rezident orthopedics Spitalul Clinic Judetean de Urgenta Oradea 4- Dr primary specialist orthopedics Spitalul Clinic Judetean de Urgenta Arad 5- Dr primary specialist orthopedics
Abstract:	This study investigates the safety and efficacy of intra-articular (IA) sodium hyaluronate (HA) in the treatment of synovial joint osteoarthritis. This is a prospective, observational study. The patients were given five IA of HA at interval of one week. Efficacy included self-reported pain Visual Analog Scale (VAS) and the NSAID intake. The patients did not report any adverse reaction during the study. The study shows that IA HA injection decreases the pain (VAS) and reduces the NSAID intake in OA.
Keywords:
References:	Dahl LB, Dahl IM, Engstrom-Laurent A, Granath K. Concentration and molecular weight of sodium hyaluronate in synovial fluid from patients with rheumatoid arthritis and other arthropathies. Ann Rheum Dis. 1985 DeVane CL. Substance P:a new era, a new role. Pharmacotherapy 2001 Fries JF. NSAID gastropathy: the second most deadly rheumatic disease. Epidemiology andrisk appraisal. J Rheumatol 1991 Frizziero L, Govoni E, Bacchini P. Intra-articular hyaluronic acid in the treatment of osteoarthritis of the knee :clinical and morphological. Clinical Exp Rheum 1998 Foti C, Cisari C, Carda S, Giordan N, Rocco A, Frizziero A, Della Bella G. A prospective observational study of the clinical efficacy and safety of intra-articular sodium hyaluronate (MW 1500-2000 KDa; Hyalubrix®) in synovial joints with osteoarthritis European journal of psychical and rehabilitation medicine vol 47 2011 Griffin MR, Yared A, Ray WA. Non steroidal antiinflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol 2000 Hayes Hyaluronic Acid/Viscosupplementation A Health Technology Assessment Prepared for Washington State Health Care Authority FINAL REPORT – October 14, 2013 Henry D. Non-steroidal anti-inflammatory drugs and the risk of development of congestive cardiacfailure and functional renal impairment. Proceedings of the international conference on inflammopharmacology, San Francisco, 1997. Karlsson J, Sjögren LS, Lohmander LS. Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double-blind, parallel-design multicenter study. Rheumatology 2002 Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG, Liang MH, Pillemer SR, Steen VD, Wolfe F: Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998 Lussier A, Cividino AA, McFarlane CA, Olszynski WP, Potashner WJ, De Medicis R. Viscosupplementation with hylan for the treatment of osteoarthritis:findings from clinical practice in Canada. J Rheumatol 1996 Marshall KW. Viscosupplementation for osteoarthritis: current status, unresolved issues and future directions. J Rheumatol. 1998 Migliore A. Hip viscosupplementation under ultra-sound guidance riduces NSAID consumption in symptomatic hip osteoarthritis patients in a long follow-up. Data from italian registry 2011 Moore RA, Philips CJ. Cost of NSAID adverse effects to the UK National Health Service. J Med Econ 1999 National Center for Health Statistics: Prevalence of osteoarthritis in adults by age, sex, race and geographic area: United States 1960-62. Vital and Health Statistics no. 15, series 11 Washington, DC: Government Printing Office; 1966. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med 2000 Schieb F. Intraartikular injizierte Hyaluronsaure bei Arthropathien. Arthritis Rheum 2003 Straube S, Tramer MR, Moore RA, Derry S, Mcquai HJ. Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use. BMC Gastroenterol 2009 Towheed T, Shea B, Wells G, Hochberg M. Analgesia and non-aspirin, non steroidal anti-inflammatory drugs for osteoarthritis of the hip (Cochrane review). In: The Cochrane library, issue 1. Oxford: Update Software, 2000 Yasui T, Akatsuka M, Tobetto K. Effects of hyaluronan on the production of stromelysin and tissue inhibitor of metalloproteinase-1 (TIMP-1) in bovine articular chondrocytes. Biomed Res 1992 Zhang W, Moskowitz RW, Nuki G, Abramsons S, Altman RD, Arden N, Bierma-Zeistra S, Brandt KD, Croft P, Doherty M, Dougades M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence- based expert consensus guidelines. Osteoarthritis Cartilage 2008;
*Correspondence:

About The Author

dti